McIntyre RS, Kwan ATH, Rosenblat JD, Teopiz KM, Mansur RB
GLP-1 receptor agonists pass the bloodbrain barrier and directly engage with GLP-1 receptors in essential appetite-regulating sites of the hypothalamus and brainstem (Trapp and Brierley 2022)
Some individuals view lower doses as a way to support short- or medium-term metabolic goals rather than committing to higher doses long term
In many populated areas, talent exists, but the challenge is finding the right talent with the right skill set who will stay, perform, and align with the organization
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
GLP-1 Medications and Muscle Loss: What the Published Research Actually Shows Here's the real reason this category exists: when you lose weight on a GLP-1 medication, not all of that weight comes from fat